P/E at 34.7 vs Industry's 31.09: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Market Confidence?

The current P/E of 34.7 for Sun Pharmaceutical Industries Ltd stands above the sector average of 31.09, indicating that investors are willing to pay a premium of nearly 11.6% for its earnings. This valuation premium may reflect expectations of superior earnings stability or growth prospects relative to peers. However, it also raises questions about whether the premium is justified given the stock’s recent performance and broader sector dynamics. Sun Pharma’s market capitalisation of ₹4,26,685.73 crore places it firmly in the large-cap category, which often commands higher valuation multiples due to perceived lower risk and greater liquidity.

Performance Across Timeframes: Mixed Signals

Examining the stock’s returns reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has marginally declined by 0.39%, outperforming the Sensex’s 5.69% loss over the same period. This relative resilience is more pronounced in shorter timeframes: the stock gained 2.35% over three months and 2.76% over one month, while the Sensex fell 13.89% and 10.55% respectively. Year-to-date, the stock is up 3.41%, contrasting with the Sensex’s 13.70% decline. This divergence suggests that Sun Pharma has been a relative outperformer amid broader market weakness, though the gains are modest rather than spectacular.

However, the one-week and one-day performances show slight underperformance and outperformance respectively, with the stock down 0.96% over the week versus the Sensex’s 3.32% fall, but up 1.25% on the day compared to the Sensex’s 1.17% gain. This short-term volatility may reflect market reactions to recent news or sector developments — is this a temporary fluctuation or a sign of shifting momentum?

Moving Average Configuration: Bullish Technical Setup

Technically, Sun Pharmaceutical Industries Ltd is trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This comprehensive positioning above short, medium, and long-term averages indicates a strong upward trend and suggests sustained buying interest. The stock is also just 3.32% away from its 52-week high of ₹1850.95, underscoring its recent strength. The opening gap up of 2% today and intraday high of ₹1791.5 further reinforce this positive technical momentum. Sun Pharma’s ability to maintain levels above these averages may be a key factor in its relative outperformance versus the broader market.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks that have declared results, 16 reported positive outcomes, 9 were flat, and 9 negative. This distribution suggests a sector grappling with uneven growth and profitability pressures. Against this backdrop, Sun Pharmaceutical Industries Ltd’s relative stability and modest outperformance stand out. The stock’s premium valuation may partly reflect its ability to navigate sector headwinds better than many peers, but it also raises the question of whether the premium is sustainable given the sector’s patchy earnings environment — how will this sector backdrop influence the stock’s near-term trajectory?

Rating Reassessment: Previously Hold, Now Updated

On 23 Feb 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold status. While the current rating is not disclosed, this reassessment reflects a fresh evaluation of the company’s fundamentals, valuation, and technical outlook. The Mojo Score of 72.0 indicates a solid overall assessment, consistent with the stock’s large-cap stature and steady performance. What is the current rating for Sun Pharma following this reassessment? This question remains central for investors seeking clarity amid the stock’s valuation premium and mixed performance signals.

Long-Term Performance: Strong Historical Gains

Looking beyond the recent year, Sun Pharmaceutical Industries Ltd has delivered impressive long-term returns. Over three years, the stock has gained 82.81%, significantly outperforming the Sensex’s 27.85% rise. The five-year return is even more striking at 204.04%, compared to the Sensex’s 49.55%. However, the 10-year return of 110.06% trails the Sensex’s 190.27%, indicating that while the stock has been a strong performer in recent years, it has lagged the broader market over the last decade. This long-term context adds nuance to the current valuation premium and recent performance trends — should investors hold, buy more, or reconsider their position?

Conclusion: A Stock Balancing Premium Valuation and Mixed Momentum

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a modest premium to its sector, supported by a strong technical setup and relative outperformance in recent months. The stock’s position above all major moving averages and proximity to its 52-week high underscore positive momentum, while its long-term returns demonstrate solid wealth creation over the past five years. Yet, the modest one-year decline and the mixed sector results highlight ongoing challenges. The recent rating reassessment from Hold invites further scrutiny — what does the current rating imply for investors navigating this valuation-performance tension?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →